- AXN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $5.7 million.
- AXN has traded 752,536 shares today.
- AXN is trading at 2.15 times the normal volume for the stock at this time of day.
- AXN is trading at a new low 13.00% below yesterday's close.
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in AXN with the Ticky from Trade-Ideas. See the FREE profile for AXN NOW at Trade-Ideas More details on AXN: Aoxing Pharmaceutical Company, Inc., a specialty pharmaceutical company, researches, develops, manufactures, and distributes various narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The average volume for Aoxing Pharmaceutical has been 954,000 shares per day over the past 30 days. Aoxing has a market cap of $125.7 million and is part of the health care sector and drugs industry. The stock has a beta of 6.14 and a short float of 1.2% with 0.16 days to cover. Shares are up 466.8% year-to-date as of the close of trading on Monday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Aoxing Pharmaceutical as a sell. Among the areas we feel are negative, one of the most important has been very high debt management risk by most measures. Highlights from the ratings report include:
- The debt-to-equity ratio is very high at 5.89 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Along with this, the company manages to maintain a quick ratio of 0.32, which clearly demonstrates the inability to cover short-term cash needs.
- Compared to other companies in the Pharmaceuticals industry and the overall market, AOXING PHARMACEUTICAL CO INC's return on equity significantly trails that of both the industry average and the S&P 500.
- The gross profit margin for AOXING PHARMACEUTICAL CO INC is currently very high, coming in at 85.62%. It has increased significantly from the same period last year. Despite the strong results of the gross profit margin, AXN's net profit margin of 11.80% significantly trails the industry average.
- Net operating cash flow has significantly increased by 140.85% to $1.78 million when compared to the same quarter last year. In addition, AOXING PHARMACEUTICAL CO INC has also vastly surpassed the industry average cash flow growth rate of -24.06%.
- This stock has increased by 423.52% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the future course of this stock, we feel that the risks involved in investing in AXN do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
- You can view the full Aoxing Pharmaceutical Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.